Clinical Trial

Psyence Appoints Intellectual Property Expert to Its Board of Directors

TORONTO, July 11, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is…

12 months ago

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing…

12 months ago

Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders

SAN FRANCISCO, CA / ACCESSWIRE / July 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced…

12 months ago

New Disease Modifying Drug for Alzheimer’s Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring

Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal…

12 months ago

Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial

San Diego, California--(Newsfile Corp. - July 6, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical…

12 months ago

Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.LOS ANGELES, July 10, 2023 (GLOBE…

12 months ago

Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.LOS ANGELES, July 10, 2023 (GLOBE…

12 months ago

Route 92 Medical Announces Appointment of Chris Hartman as Chief Commercial Officer

Chris Hartman Chris Hartman, Chief Commercial Officer, Route 92 MedicalSAN MATEO, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Route 92…

12 months ago

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of…

12 months ago

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on…

12 months ago